logo
Black maternal mortality rate rises as other groups see declines

Black maternal mortality rate rises as other groups see declines

CBS News13-02-2025

MIAMI - The racial gap in maternal mortality is widening, with Black women being the only racial group to see an increase in pregnancy-related deaths between 2022 and 2023, according to new data from the Centers for Disease Control and Prevention.
The CDC found that Black women are now 3.5 times more likely to die from pregnancy-related causes than white women, up from 2.5 times in 2019.
Midwifery, doula services
The Southern Birth Justice Network (SBJN), a nonprofit focused on maternal health equity, is working to expand access to midwifery and doula services, which they say can help address the crisis.
Carmen Legacy, a mother who chose a midwife for both of her pregnancies, said she sought out extended care she felt was lacking in hospitals.
"I had that personal care. I felt like I was talking to someone that was listening to me and my body," Legacy said.
Jamarah Amani, executive director of SBJN, said the issue is systemic.
"It's something that we've known for a long time, that there are severe factors related not to the race of the person but to racism in the system," Amani said.
Barriers to maternal care
Black women saw their maternal mortality rate increase from 49.5 deaths per 100,000 live births to 50.3 over one year, while every other racial group experienced declines.
"We know that Black women are less likely to be listened to in the hospital. They are more likely to have their pain and symptoms denied, more likely to be gaslit by their physicians, and more likely to feel misunderstood and not trust the system, because the system has not proven to be trustworthy," Amani said.
Legacy shared similar concerns.
"It was scary because you don't know what's going to happen, but I felt supported because I had such a big support system. I had a birth team of five people," she said.
The role of midwives
According to the Cleveland Clinic, only 6 to 8% of U.S. pregnancies are classified as high-risk, roughly 30,000 to 50,000 annually. Amani said midwives are critical for managing the majority of pregnancies that are low-risk.
"Midwives are the experts in low-risk pregnancy, birth, and postpartum care. Of course, we collaborate with physicians if someone is high-risk," Amani said.
Partnerships to improve outcomes
The Southern Birth Justice Network is working to integrate midwifery practices into hospital settings. Through its Black Maternal Infant Health Equity Collaborative, SBJN trains doulas to work alongside doctors at hospitals like Jackson Health.
In a statement, Jackson Health said its partnership with SBJN has improved maternal health outcomes and reduced complications.
"Hand in hand with community partners, healthcare providers, and families, The Women's Hospital at Jackson Memorial has launched a program to add doulas into our health system, providing a full-scope support program for moms-to-be," the statement read.
"At Jackson, we're committed to reducing disparities in maternal care. We're proud of the progress we've made and the partnerships we've created to improve maternity health within our community."
As maternal mortality rates remain a concern, advocates continue to push for systemic change to ensure Black women receive equitable, life-saving care during pregnancy and childbirth.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Anti-DEI group targets Geisinger College of Health Sciences over program
Anti-DEI group targets Geisinger College of Health Sciences over program

Yahoo

time2 hours ago

  • Yahoo

Anti-DEI group targets Geisinger College of Health Sciences over program

SCRANTON — A national anti-DEI group has targeted the Geisinger College of Health Sciences with recent filings of discrimination complaints. Virginia-based Do No Harm purported in news releases in March and June that it filed separate complaints with two federal agencies against the college, citing as discriminatory its federally funded Center of Excellence for Diversity and Inclusion and a summer program that aimed to help students from Black, Hispanic or Native American communities that are underrepresented in the medical field transition into medical school. The Do No Harm discrimination complaints come amid President Donald Trump's efforts to dismantle DEI, or diversity, equity and inclusion, programs in the public and private sectors. Trump issued executive orders in the first week of his second term targeting DEI initiatives. 'Geisinger College of Health Sciences did a thorough review of our programs after the presidential executive orders were issued to ensure compliance. The pre-matriculation program referenced in the (Do No Harm) complaint ended in 2024 and is no longer active,' Geisinger CHS said in a statement. Do No Harm is labeled by the Southern Poverty Law Center as an 'anti-LGBTQ+ hate group.' Critics of the SPLC say it's politically biased and its definition of hate group is overly broad. Do No Harm first filed a complaint with the U.S. Department of Health and Human Services on March 19 against Geisinger CHS, according to a news release posted on the Do No Harm website. A member of Do No Harm then filed a similar complaint June 5 with the U.S. Department of Education, because Geisinger 'did not learn its lesson' from the initial complaint filed with HHS, the advocacy organization announced in another news release. The Times-Tribune could not verify that the complaints were filed with both departments, and whether either agency investigated the allegations or took any actions. The U.S. Department of Health and Human Services and the U.S. Department of Education through separate representatives said they do not confirm the existence of complaints. Do No Harm, established in April 2022, claims it has 17,000 members, including doctors, nurses, physicians and concerned citizens, and cites its mission as safeguarding health care from ideological threats. 'Do No Harm seeks to highlight and counteract divisive trends in medicine, such as 'Diversity, Equity and Inclusion' and youth-focused gender ideology,' the organization's website says. According to the SPLC, Do No Harm in 2024 filed eight lawsuits challenging programs such as scholarships and fellowships for marginalized people. 'The group claims that the practice of nonprofit organizations like the American Association of University Women to provide fellowships to students of color and LGBTQ+ students — groups historically underrepresented in academia and medicine — harms patients by requiring medical schools to accept or fund unqualified candidates. According to the group, the case was dismissed 'after AAUW agreed to drop the racial criteria in the fellowship's selection process,'' the SPLC website says. According to the website of Geisinger College of Health Sciences, it is the research and education arm of the Geisinger health system. Established in 2022, the college unifies the Geisinger Commonwealth School of Medicine, Geisinger School of Nursing, Geisinger School of Graduate Education, graduate medical education, Center for Faculty and Professional Development and more. * Geisinger College of Medicine in Scranton on Monday, June 9, 2025. (REBECCA PARTICKA/STAFF PHOTOGRAPHER) * Geisinger College of Medicine in Scranton on Monday, June 9, 2025. (REBECCA PARTICKA/STAFF PHOTOGRAPHER) * Geisinger College of Medicine in Scranton on Monday, June 9, 2025. (REBECCA PARTICKA/STAFF PHOTOGRAPHER) Show Caption 1 of 3 Geisinger College of Medicine in Scranton on Monday, June 9, 2025. (REBECCA PARTICKA/STAFF PHOTOGRAPHER) Expand

Anti-DEI group targets Geisinger College of Health Sciences over program
Anti-DEI group targets Geisinger College of Health Sciences over program

Yahoo

time3 hours ago

  • Yahoo

Anti-DEI group targets Geisinger College of Health Sciences over program

SCRANTON — A national anti-DEI group has targeted the Geisinger College of Health Sciences with recent filings of discrimination complaints. Virginia-based Do No Harm purported in news releases in March and June that it filed separate complaints with two federal agencies against the college, citing as discriminatory its federally funded Center of Excellence for Diversity and Inclusion and a summer program that aimed to help students from Black, Hispanic or Native American communities that are underrepresented in the medical field transition into medical school. The Do No Harm discrimination complaints come amid President Donald Trump's efforts to dismantle DEI, or diversity, equity and inclusion, programs in the public and private sectors. Trump issued executive orders in the first week of his second term targeting DEI initiatives. 'Geisinger College of Health Sciences did a thorough review of our programs after the presidential executive orders were issued to ensure compliance. The pre-matriculation program referenced in the (Do No Harm) complaint ended in 2024 and is no longer active,' Geisinger CHS said in a statement. Do No Harm is labeled by the Southern Poverty Law Center as an 'anti-LGBTQ+ hate group.' Critics of the SPLC say it's politically biased and its definition of hate group is overly broad. Do No Harm first filed a complaint with the U.S. Department of Health and Human Services on March 19 against Geisinger CHS, according to a news release posted on the Do No Harm website. A member of Do No Harm then filed a similar complaint June 5 with the U.S. Department of Education, because Geisinger 'did not learn its lesson' from the initial complaint filed with HHS, the advocacy organization announced in another news release. The Times-Tribune could not verify that the complaints were filed with both departments, and whether either agency investigated the allegations or took any actions. The U.S. Department of Health and Human Services and the U.S. Department of Education through separate representatives said they do not confirm the existence of complaints. Do No Harm, established in April 2022, claims it has 17,000 members, including doctors, nurses, physicians and concerned citizens, and cites its mission as safeguarding health care from ideological threats. 'Do No Harm seeks to highlight and counteract divisive trends in medicine, such as 'Diversity, Equity and Inclusion' and youth-focused gender ideology,' the organization's website says. According to the SPLC, Do No Harm in 2024 filed eight lawsuits challenging programs such as scholarships and fellowships for marginalized people. 'The group claims that the practice of nonprofit organizations like the American Association of University Women to provide fellowships to students of color and LGBTQ+ students — groups historically underrepresented in academia and medicine — harms patients by requiring medical schools to accept or fund unqualified candidates. According to the group, the case was dismissed 'after AAUW agreed to drop the racial criteria in the fellowship's selection process,'' the SPLC website says. According to the website of Geisinger College of Health Sciences, it is the research and education arm of the Geisinger health system. Established in 2022, the college unifies the Geisinger Commonwealth School of Medicine, Geisinger School of Nursing, Geisinger School of Graduate Education, graduate medical education, Center for Faculty and Professional Development and more. * Geisinger College of Medicine in Scranton on Monday, June 9, 2025. (REBECCA PARTICKA/STAFF PHOTOGRAPHER) * Geisinger College of Medicine in Scranton on Monday, June 9, 2025. (REBECCA PARTICKA/STAFF PHOTOGRAPHER) * Geisinger College of Medicine in Scranton on Monday, June 9, 2025. (REBECCA PARTICKA/STAFF PHOTOGRAPHER) Show Caption 1 of 3 Geisinger College of Medicine in Scranton on Monday, June 9, 2025. (REBECCA PARTICKA/STAFF PHOTOGRAPHER) Expand

Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue
Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue

Miami Herald

time4 hours ago

  • Miami Herald

Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue

Even the Hamburglar didn't see this one coming. Excessive weight has been a persistent problem in America, where at least one in five adults in each U.S. state is living with obesity, according to the Centers for Disease Control and Prevention. Don't miss the move: Subscribe to TheStreet's free daily newsletter As obesity rates have risen, so have scientists' efforts to address this serious health issue, which can cause asthma, heart disease, stroke, type 2 diabetes and even some cancers. Early attempts to treat obesity came to the market as early as the 1930s. Amphetamines were the prevalent treatment in the 1940s and 1950s and demand continued into the 1990s. Glucagon-like peptide-1 agonists, which mimic the action of the naturally occurring hormone GLP-1, have been available for about two decades. GLP-1 medications, including Ozempic, Wegovy, Zepbound and Mounjaro, have been used for years to treat Type 2 diabetes, and studies have found that they are also effective at encouraging weight loss. Wegovy and Ozempic are manufactured by Novo Nordisk (NVO) , while Eli Lilly (LLY) makes Zepbound and Mounjaro. Image source:One investment firm says increased use of these medications could have serious implications for two of the biggest names in the fast-food industry: McDonald's (MCD) and Domino's Pizza (DPZ) . The market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, is still new and continuously evolving, Goldman Sachs said in a May 22 report. More Restaurants Beloved Mexican restaurant closing iconic location after 63 yearsMajor restaurant chain quietly closes several locationsIconic restaurant closing its doors after 32 years The investment firm lowered its projections for such medication and now forecasts the global market to reach $95 billion by 2030. That's down from the previous estimate of $130 billion to reflect trends influencing how the drugs are priced, how long patients stay on them, and how patient populations are segmented. Goldman lowered its U.S. market projections to a peak of $70 billion, but the firm sees room for greater penetration in markets outside the U.S. Goldman forecasts a market peak of $50 billion outside the US, compared with $35 billion previously. A survey of more than 50 doctors in the US found that lower doses of anti-obesity medications are working well for a majority of patients and insurance coverage is the most important factor in the decision-making process, Goldman Sachs wrote. "But to be clear, even with this moderated forecast, we see a significant growth opportunity for both existing players as well as new entrants into this market," said Asad Haider, head of the health-care business unit within Goldman Sachs Research. Demand for GPL-1 drugs could dramatically hinder the food and restaurant industries, according to a study from Cornell's SC Johnson College of Business and the data firm Numerator. The report, entitled "The No Hunger Games," found that households with at least one user of GLP-1 drugs reduced its grocery spending by about 6% within six months of starting the drugs. The spending cut was as much as 9% for higher-income households. "We also find an 8.6% decline in spending at fast-food chains, coffee shops and limited-service restaurants," the study said. "Our findings highlight the potential for GLP-1 medications to significantly change food demand, a trend with increasingly important implications for the food industry as GLP-1 adoption continues to grow." The study warned that common side effects of GLP-1 medications, such as nausea, vomiting and gastrointestinal discomfort, have reportedly led to reduced adherence or discontinued use for some patients. Related: McDonald's analyst grills new stock price target on McCrispy reaction "Moreover, their long-term efficacy and safety remain areas of ongoing investigation," the report said. Redburn Atlantic analyst Chris Luyckx focused on the growing adoption of GLP-1 in recent research reports. Luyckx double-downgraded McDonald's to sell from buy with a price target of $260, down from $319. The analyst expects the GLP-1 weight-loss drugs to suppress consumer appetites and says they present an underappreciated longer-term threat for McDonald's. A 1% drag on sales today "could easily build to 10% or more over time," particularly for restaurant brands skewed toward lower-income consumers, the analyst tells investors in a research note. McDonald's stock was down about 1.3% at last check and is up 18.5% from a year ago. Redburn Atlantic also initiated coverage of Domino's Pizza with a sell rating and $340 price target. Domino's, the world's largest pizza chain, faces the heaviest pressure from adoption of GLP-1 weight loss drugs, with high exposure to dinner occasions and lower-income consumers, the firm said. Redburn Atlantic said the company's organic traffic remains weak, with carry-out far outpacing delivery. Challenged system-sales growth and elevated consensus expectations present downside risk for Domino's, the firm said. McDonald's closed regular trading on June 10 down 1.4% at $300.43. Domino's shares were off 2.7% at $455.49. Related: Fund-management veteran skips emotion in investment strategy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store